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There is overwhelming evidence that G-protein–coupled receptors
(GPCRs) exhibit several distinct low-energy conformations, each of
which might favor binding to different ligands and/or lead to dif-
ferent downstream functions. Understanding the function of such
proteins requires knowledge of the ensemble of low-energy con-
figurations that might play a role in this pleiotropic functionality.
We earlier reported the BiHelix method for efficiently sampling
the (12)7 = 35 million conformations resulting from 30° rotations
about the axis (η) of all seven transmembrane helices (TMHs),
showing that the experimental structure is reliably selected as
the best conformation from this ensemble. However, various
GPCRs differ sufficiently in the tilts of the TMHs that this method
need not predict the optimum conformation starting from any
other template. In this paper, we introduce the SuperBiHelix
method in which the tilt angles (θ, φ) are optimized simultaneously
with rotations (η) efficiently enough that it is practical and suffi-
cient to sample (5 × 3 × 5)7 = 13 trillion configurations. This
method can correctly identify the optimum structure of a GPCR
starting with the template from a different GPCR. We have vali-
dated this method by predicting known crystal structure confor-
mations starting from the template of a different protein struc-
ture. We find that the SuperBiHelix conformational ensemble in-
cludes the higher energy conformations associated with the active
protein in addition to those associated with the more stable in-
active protein. This methodology was then applied to design and
experimentally confirm structures of three mutants of the CB1
cannabinoid receptor associated with different functions.
protein structure prediction | A2A adenosine receptor |
β2-adrenergic receptor | constitutive activity | functional selectivity
G-protein–coupled receptors (GPCRs) [also referred to asseven-transmembrane receptors (7TMRs)] are integral mem-
brane proteins that play a central role in transmembrane (TM)
signal transduction. This largest superfamily in the human ge-
nome with ∼800 receptors identified (1, 2) is activated by a va-
riety of bioactive molecules, including biogenic amines, peptides,
and hormones that modulate the activity of 7TMRs to effect
regulation of essential physiological processes (e.g., neurotrans-
mission, cellular metabolism, secretion, cell growth, immune
defense, and differentiation) through G-protein–coupled and/or
β-arrestin–coupled signaling pathways (3) (Fig. 1A). A structural
understanding of their pleiotropic function will have a tremen-
dous and broad impact, as the disregulation of these receptors
often plays an important role in major disease pathologies (1, 4).
Malfunctions in GPCRs play a part in diseases such as ulcers,
allergies, migraines, anxiety, psychosis, schizophrenia, hyperten-
sion, asthma, congestive heart failure, Parkinson, and glaucoma.
GPCRs are of great interest pharmacologically, as the targets of
50% of recently released drugs and 25 of the top 100 best-selling
drugs (5).
The pleiotropic nature of these receptors arises because ∼10–
20 conformations of the wild-type (WT) GPCR have sufficiently
close energies that one or another can be stabilized by inter-
actions with various ligands, which in turn can lead to ligand-
dependent functionality. Moreover, it has been shown (6–8) that
even a single mutation can change the relative ordering of these
low-lying conformations sufficiently to dramatically change the
affinity to various ligands and indeed even the functionality in
terms of G-protein coupling and downstream signaling (3). The
current structural, thermodynamic, and functional knowledge of
GPCRs suggests an emerging conformational-ensemble picture
like the one shown in Fig. 1B (9), which provides a schematic of
GPCR conformations in different scenarios using WT as a ref-
erence. The relative thermodynamic ordering of this pleiotropic
ensemble of low-energy GPCR conformations can change depend-
ing on the conditions: mutations, presence of ligands, and/or pres-
ence of other proteins like G proteins, which in turn modifies the
physiological function.
This pleiotropic ensemble also has profound implications for
the ability to control receptor pharmacology, especially associ-
ated with receptor target-induced side effects, when the targeted
receptor activates both beneficial and undesirable signaling
pathways. An example is the niacin receptor GPR109A. Niacin is
therapeutically beneficial as an antilypolytic agent (via G-protein–
mediated pathways), but it also causes cutaneous flushing, which
has been directly linked to the activation of β-arrestin 1 pathways
(10). An analog of this molecule that does not affect the G-protein
pathways but destabilizes the coupling to β-arrestin 1 and blocks
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that pathway (shown with red arrow in Fig. 1A) will be highly
desirable. This requires a structural understanding of how dis-
tinct conformations selectively couple to specific pathways under
various conditions.
Despite the great interest in GPCRs, progress in obtaining
experimental atomic-level structures essential for understanding
the nature of activation and for design and optimization of drug
candidates has been slow, due to challenges involved in GPCR
expression, purification, and crystallization. Breakthroughs in
membrane protein structural biology techniques (11) are accel-
erating GPCR structure determinations and have resulted in
structures (crystal/NMR) for ∼19 GPCRs, where a majority have
been solved in one inactive form of the receptor. Three of these
receptors have also been crystallized in functionally distinct
conformations [β2 with Gs (12), meta II rhodopsin (13), and the
partially active form of A2A receptor (14)], whose comparison
with the respective inactive conformations provides structural
insight into their activation. One of these receptors (Neurotensin
receptor 1) has been crystallized only in the putatively active
conformation (15). Indeed, Kim et al. (16) found for the A3
adenosine receptor that the optimum conformation for binding
four selective agonists was the 15th in the hierarchy of con-
formations for the apo protein, whereas four selective antago-
nists preferred either the second or the third conformation.
Thus, each receptor putatively has multiple active conformations
(Fig. 1B), making it essential to obtain a method of predicting
GPCR structures that does not require homologous experi-
mental structures and that can determine the ensemble of low-
lying structures.
To provide the means for determining this ensemble of low-
lying seven-helix bundle conformations, we propose and validate
here the SuperBiHelix method, which aims to select from a
complete set of seven-helix packings or conformations the en-
semble of low-energy GPCR structures that could play a role in
ligand binding and/or activation. The SuperBiHelix method
builds upon the BiHelix method (17). We showed earlier that,
starting with the known X-ray structure, the BiHelix method
identifies correctly the optimum packing from the (12)7 = 35
million conformations differing by independent 30° rotations
about the axes of the seven transmembrane helices. However,
starting with some template (previous experimental or predicted
structure) the BiHelix method does not necessarily identify the
correct tilts of the helices (7, 9, 18) in the membrane. In this
paper, we generalize the BiHelix concept to optimize the helical
tilts (θ, φ) simultaneous with the helical rotations (η), which
we refer to as SuperBiHelix. We demonstrate here that, starting
with the X-ray template, say for A2A, the SuperBiHelix procedure
outlined below correctly predicts the structure for β2-adrenergic
receptor and vice versa. Also, the method is predictive as ex-
emplified by the design of CB1 receptor mutants with altered
G-protein coupling efficacy, which were later confirmed experi-
mentally by GRPγS assays (7).
Methodology
SuperBiHelix and SuperCombiHelix. The SuperBiHelix procedure starts with
a GPCR bundle template, obtained either from X-ray experiments or from
previously predicted and validated GPCR structures. This template is defined
by the 6 × 7 = 42 degrees of freedom: x, y, h, θ, ϕ, and η values for each of the
seven TM helices, as described earlier (17). Because some helices may have
kinks and bends, the helical axis is defined as its least moment of inertia. The
hydrophobic center (HPC) residue h is the residue that crosses the z =
0 plane, which is defined as the plane that runs through the center of the
lipid bilayer. This center is calculated from the hydrophobic profile obtained
either by our PredicTM procedure (19) or by homology to the template
structure prealigned to an implicit membrane, as in the OPM database (20).
The x axis is defined along the vector pointing from the HPC of TM3 (which is
near the middle of the bundle), to the HPC of TM2. These definitions of the x
axis and z axis implicitly define the y axis. The (x, y) position of the helix HPCs
in the z = 0 reference plane is defined by the template and is not currently
sampled by SuperBiHelix (this could be included but at substantially in-
creased cost). The helix HPC residue (h) could be optimized by translating the
helix along its helical axis, but we do not currently do this for the standard
SuperBiHelix method. The coordinates (x, y, h) are expected to be optimized
during atomistic membrane bilayer molecular dynamics of the predicted
ensemble of conformations. This leaves 3 degrees of freedom to be sampled
for each of the seven helices: θ, the tilt angle of the TM helix axis from the z
axis (that is perpendicular to the membrane plane); ϕ, the sweep (or azi-
muthal) angle of the helix axis about the z axis; and η, the rotation of the
helix around the helical axis.
The SuperBiHelix procedure starts with an input GPCR bundle determined
by 42 template variables defined earlier and would normally be called
a homology model. Just as in the BiHelix method (17), we approximate the
energy as the sum over pairwise interactions between each of the 12 pairs of
interacting helices. For each of these interacting pairs, we sample θ, ϕ, and η,
while ignoring the other five helices, leading to the BiHelix energies.
SCREAM (21) is used to predict the side-chain placements, which are then
minimized for 10 steps with the backbone fixed (to resolve any bad con-
tacts). This procedure is illustrated in Fig. 2A.
Once the 12 pairs of BiHelix energies have been determined for all possible
combinations of θ, ϕ, and η, we combine these energies to predict a mean
field energy of the entire bundle for effectively (3*5*5)7 ∼ 1013 con-
formations. These BiHelix energies are partitioned into intrahelical and
interhelical components to avoid multiple counting of the intrahelical con-
tributions, and the energy of the entire complex is then calculated, as de-
scribed in SI Text (17). Although the calculation of the energy of a complex
based on its BiHelix energies is very fast, the calculation of all possible
configurations is still computationally expensive. In practice, we generally
sample three values of θ, five values of ϕ, and five values of η, leading to
(3*5*5)7 ∼ 1013 total bundle conformations. To minimize the number of
total bundle energies to be calculated, we developed a procedure to de-
termine which conformations for each helix are most favorable.
To determine the conformations for each helix likely to lead to low-energy
bundles, we partitioned the seven-helix bundle into three QuadHelix bun-
dles, as shown in Fig. 2B. It is feasible to estimate the total BiHelix energies of
the three QuadHelix bundles because it requires only 3*(3*5*5)4 ∼ 108
bundle energies. The 2,000 structures with the lowest energy for each
QuadHelix are listed by increasing energy. Then, the best 36 conformations
for each helix are selected. This list of 36 conformations for a specific helix
depends on how many QuadHelix bundles contain the helix. For helices 1, 4,
Fig. 1. Illustration of the pleiotropic ensemble and
its effects. (A) Balanced signaling by GPCRs. (B) Func-
tional/thermodynamic view of GPCR conformations.
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and 6, which only exist in one QuadHelix bundle, the 36 unique single helix
conformations are selected that correspond to the lowest energy QuadHelix
conformations. For helices 2, 5, and 7, which exist in two QuadHelix bundles,
the top 18 unique single-helix conformations are selected independently
from both QuadHelix bundles and then combined. Finally, for helix 3, which
exists in all three QuadHelix bundles, the top 12 unique single-helix con-
formations are selected independently and combined. If a helix conforma-
tion is the same in two QuadHelix bundles, then the next configuration in
the latter QuadHelix (going in the order TM1-TM2-TM3-TM7, TM2-TM3-
TM4-TM5, and TM3-TM5-TM6-TM7) is chosen. At the end, 36 unique con-
figurations for each TM helix are selected. Last, from each individual helical
conformation list, the 36 conformations for each helix are used to calculate
the energy of 367 ∼ 8 × 1010 full bundles. We then output the 2,000 best
energy structures from this procedure.
In the SuperComBiHelix step, these top 2,000 helical bundles (from
SuperBiHelix) are built and the side chains are reassigned with SCREAM (21),
so they will likely have different conformations than in the BiHelix limit.
Then the structure is minimized for 10 steps. This energy ranking for
SuperComBiHelix will be different (and more accurate) than that for
SuperBiHelix because all seven helices are present instead of just two. This
procedure results in the ensemble of low-energy conformations most likely
to play a role in binding of ligands and activation of the GPCR.
Extensive testing on these methods, shown below in Validation, led to
several improvements in the procedure. During the side-chain prediction
steps in SuperBiHelix and SuperComBiHelix, SCREAM must be used with
a 0.5-Å resolution library instead of the 1.0-Å resolution library that is the
default for SCREAM. Additionally, for the best results we mutate the final
two residues of the C and N termini to alanine for each helix during the
SuperBiHelix step. Then, before the SuperComBiHelix step, these mutated
alanine residues are mutated back to their original residues for the building
of the full bundles. This step reduces artificial long-range electrostatic
interactions between charged groups that would be located in the polar
head group region of the lipid bilayer.
Binding Site Prediction. For the ligand docking step, we use techniques de-
veloped as part of the DarwinDock/GenDock protocols (22), which aims at
sampling all possible poses before evaluating energies and then groups the
poses into families ordered by the energy of the family head to minimize the
number of poses used for energy evaluation. The docking methodology is
described in SI Text.
Validation
SuperBiHelix on Crystal Helices in the Correct Template. The
SuperBiHelix and SuperComBiHelix procedures were devel-
oped by testing them on helices from one crystal structure in the
template of another crystal structure. During these procedures,
the extracellular/intracellular loops and the N/C termini were
not present, assuming that they do not exert a significant effect on
the TM helix bundle conformations. It is also important to de-
termine whether performing SuperBiHelix and SuperComBiHelix
on a crystal structure itself returns the original structure. There-
fore, SuperBiHelix and SuperComBiHelix were run on the A2A
adenosine receptor (23) and the β2-adrenergic crystal structure
(24), sampling θ with values of −10°, 0°, and 10°, ϕ with values of
−30°, −15°, 0°, 15°, and 30°, and η with values of −30°, −15°, 0°,
15°, and 30°. BiHelix was not rerun beforehand because we had
previously analyzed (9) that the η values would be less than 30°
from the crystal structure.
We first tested how well the QuadHelix protocol worked. We
validated that, in order for the original crystal structure to show
up in the best energy SuperBiHelix and SuperComBiHelix
structures, the crystal conformation for each helix must be in that
helix’s top 36 conformations. The ranking of the crystal confor-
mation for each helix for the A2A adenosine receptor and the
β2-adrenergic receptor is shown in the Table S1. The crystal
structure conformation for each helix is in the top 36 helical
conformations. In fact, for many helices, the crystal structure is
the best conformation. Indeed, the worst ranking for a helix is for
TM6 in the β2-adrenergic receptor, which ranked number 12.
This validates that the QuadHelix protocol works well for the
A2A adenosine receptor and the β2-adrenergic receptor crystal
structures. It also suggests that it might have been sufficient
to have limited the selection to, say, the best 24 rather than
the best 36.
We next determined whether the ranking of the top 2,000
SuperBiHelix structures is improved by SuperComBiHelix. The
SuperBiHelix and SuperComBiHelix results are shown for the
β2-adrenergic receptor crystal structure in Fig. 3. In the Super-
BiHelix structures, the crystal structure is rank 78, and after
SuperComBiHelix, it is rank 25. Not only does SuperComBiHelix
cause significant improvement in the rank of the crystal structure,
it also slightly improves the backbone root-mean-squared de-
viation (rmsd) values of the top 10 structures. Another observa-
tion to note is that these backbone rmsd values are very low (<0.6
Å), showing that we are capturing near-native conformations.
The SuperBiHelix and SuperComBiHelix results for the
A2A adenosine receptors crystal structure are in Fig. 4. The
rank of the crystal structure goes from second in SuperBiHelix
to sixth in SuperComBiHelix. Although SuperComBiHelix
Fig. 2. (A) Diagram of the SuperBiHelix method, showing how the seven-
helix TM bundle is partitioned into 12 independent helix pairs. The θ, ϕ, and
η values for each helix in the pair are sampled with the other helices not
present. (B) To efficiently determine a subset of conformations for each helix
most likely to lead to the lowest energy bundles, we partition the seven-
helix bundle into three QuadHelix bundles: TM1-TM2-TM3-TM7, TM2-TM3-
TM4-TM5, and TM3-TM5-TM6-TM7.
Fig. 3. SuperBiHelix and SuperComBiHelix results for the β2-adrenergic re-
ceptor crystal structure. The top 10 structures for both SuperBiHelix and
SuperComBiHelix are shown, along the with crystal structure, which is out-
lined by dashed lines. The crystal shows up as rank 78 for SuperBiHelix and
rank 25 for SuperComBiHelix.
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makes the crystal structure rank slightly worse than in SuperBiHelix,
SuperComBiHelix significantly improves the backbone rmsd
values of the top 10 structures (≤1.0 Å).
The SuperComBiHelix results of both the β2-adrenergic and
A2A adenosine crystal structures show that the largest variation is
in the sweep angles (φ) of the helices. Neither receptor shows
any variation in TM1 and TM2. The sweep angle of TM3 differs
from the crystal structure in the A2A adenosine receptor, but not
in the β2-adrenergic receptor. The sweep angles of TM4, TM5,
TM6, and TM7 vary for both receptors. Finally, TM5 is the only
helix whose η value changes from the crystal structure, for both
receptors. Thus, it seems that TM5 is most flexible in both
receptors. Thus, SuperBiHelix and SuperComBiHelix are suc-
cessful for both the β2-adrenergic and A2A adenosine crystal
structures in returning near-native conformations, when starting
from the correct template.
SuperBiHelix on Crystal Helices in an Incorrect Template. The
SuperBiHelix and SuperComBiHelix methods were tested on the
β2-adrenergic receptor (24) in the A2A adenosine receptor (23)
template, and vice versa. The differences between the x, y, θ, ϕ,
and η values for the two templates are given in the Table S2. x
and y have only a small amount of variation between templates,
supporting the SuperBiHelix procedure, which does not sample x
and y. Additionally, ϕ and η vary more among the templates than
θ, so more ϕ and η values will need to be sampled than θ values.
To test how well SuperBiHelix predicts structures when heli-
ces are in the incorrect template, β2-adrenergic crystal helices
were given the x, y, ϕ, θ, and η values of the A2A adenosine
template, and SuperBiHelix/SuperComBiHelix steps were run,
sampling θ with values of −10°, 0°, and 10°; ϕ with values of
−30°, −15°, 0°, 15°, and 30°; and η with values of −30°, −15°, 0°,
15°, and 30°. BiHelix was not run beforehand because η only varies
by −18.8° to +4.8° between the two templates. For all of the
validation runs, each helix in the original crystal structure was
minimized without the other helices present, so that the pro-
cedure was not biased toward the crystal structure. The results in
Fig. 5 show that the SuperBiHelix and SuperComBiHelix pro-
cedures cause the backbone rmsd of predicted conformations (to
the β2-adrenergic receptor crystal structure) to go from 2.0 to 1.6
Å, a modest improvement. The 2.0-Å rmsd to the β2-adrenergic
crystal structure of the original structure in the incorrect tem-
plate, represented by all yellow in Fig. 5, is the rmsd achieved by
using homology modeling. The lowest possible rmsd, given the
angles sampled, is 1.2 Å. The conformation of TM1 is predicted
quite poorly, most likely because TM1 has the fewest interactions
with other helices: it does not have direct interaction with TM3
like the other TM helices. Additionally, Table S2 shows that, for
the x and y values, which are not sampled by SuperBiHelix, TM1
has larger deviations between the β2-adrenergic and A2A adeno-
sine templates than any other helix. Docking of the ligand
carazolol (used to crystallize the β2-adrenergic receptor) to
structures before and after this conformational sampling pro-
cedure shows that this sampling is able to improve the pharma-
cophore of the protein–ligand interactions (see SI Text for results).
For A2A adenosine helices with the x, y, ϕ, θ, and η values of
the β2-adrenergic template, SuperBiHelix and SuperComBiHelix
causes the backbone rmsd of the predicted conformations (to the
A2A adenosine receptor crystal structure) to go from 2.1 to 1.4 Å.
This is a good improvement, given that the best rmsd possible,
given the angles sampled, is 1.2 Å. The 2.1-Å rmsd to the A2A
adenosine crystal structure of the original structure in the in-
correct template, represented by all yellow in Fig. 5, is the rmsd
achieved by using homology modeling. Docking of the ligand
ZM241385 (used to crystallize the A2A adenosine receptor) to
structures before and after this conformational sampling pro-
cedure shows an improvement in the pharmacophore (see SI
Text for results), similar to the case of carazolol docking to
predicted β2-adrenergic receptor structure.
We emphasize here that the ligand is not present during the
SuperBiHelix and SuperComBiHelix procedures. The crystal
structures are typically determined with the ligand bound, so the
ligand-free crystal structure need not be the lowest energy
structure. The presence of the ligand could change the order of
the structures. Additionally, the presence of the loops could
change the ordering of the structures. However, even ignoring
such factors, the SuperBiHelix procedure provides useful pre-
dictions of new GPCR structures.
Fig. 4. SuperBiHelix and SuperComBiHelix results for the A2A adenosine
receptor crystal structure. The top 10 structures for both SuperBiHelix and
SuperComBiHelix are shown, which include the crystal structure, outlined by
dashed lines. The color scale is show in Fig. 3.
Fig. 5. SuperComBiHelix results for β2-adrenergic receptor helices in the A2A
adenosine template (Upper) and A2A adenosine receptor helices in the
β2-adrenergic template (Lower). The rmsd is the backbone rmsd to the target
crystal structure. The structure outlined by dashed lines is the structure
closest to the crystal structure, given the angles sampled. The structure in all
yellow (representing all 0° angles) is the original structure in the incorrect
template. The color scale is show in Fig. 3.
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The Effect of SuperBiHelix on Binding Site Predictions. Although
rmsd is a reasonable metric for testing SuperBiHelix, it does not
take ligand binding into account. One of the main purposes of
predicting GPCR structures is for drug design, so it is important
to measure how well ligand binding can be predicted in struc-
tures predicted by SuperBiHelix. Thus, ZM241385 was docked
into the A2A adenosine structures predicted from the β2-adrenergic
template before and after SuperBiHelix and SuperComBiHelix,
and carazolol was docked into the β2-adrenergic structures pre-
dicted from the A2A templates before and after SuperBiHelix and
SuperComBiHelix. Then these docked results were compared with
the ligand-bound crystal structures to see whether SuperBiHelix
improved docking. The ligands were also docked into the ligand-
free crystal structure for purposes of comparison.
For ZM241385 docked into the ligand-free A2A adenosine
crystal structure, the contact rmsd is 2.4 Å. For the A2A aden-
osine helices in the β2-adrenergic template before SuperBiHelix,
the lowest contact rmsd in the final 13 docked structures is 4.6 Å,
and after SuperComBiHelix it is 3.4 Å. Thus, SuperBiHelix
makes the binding site much more like that of the crystal
structure. As seen in Fig. 6, the docked ligand in the best energy
SuperComBiHelix structure is very similar to the pose in the
crystal structure. They both make strong hydrogen bonds with
N253(TM6). The docked ligand in the structure before Super-
BiHelix takes a different pose and does not form any hydrogen
bonds with N253(TM6).
We discuss the results for the carazolol docking in SI Text, with
the docked structures seen in Fig. S1. SuperBiHelix improves the
binding-site predictions for both β2-adrenergic helices in the A2A
adenosine template and A2A adenosine helices in the β2-adren-
ergic template, but it has more effect on the A2A adenosine
helices in the β2-adrenergic template. This agrees with the rmsd
calculations for SuperBiHelix, in which there is a larger effect on
the A2A adenosine helices in the β2-adrenergic template than the
β2-adrenergic helices in the A2A adenosine template.
Can SuperBiHelix Predict Inactive and Active Conformations of
a Receptor? The GPCR conformation of an activated GPCR is
expected to have higher energy than the inactive conformation,
making it a challenge to identify these higher energy confor-
mations because, without the agonist and without a nearby G
protein, these states might be too high for SuperBiHelix/Super-
CombiHelix to identify. We rely on energy ordering the final set
of conformations without ligand or G protein and there could be
too many nonactive states in between. However, for a case in
which a receptor mutant is known to be easily activated, we
might expect that our predicted ensemble of low-energy config-
urations starting with that template might include the active
conformation of that mutant receptor (discussed below). We also
describe the rhodopsin case in SI Text, in which using helices
from an inactive state (rhodopsin) in the active-like ligand-free
opsin template (seen in Fig. S2) allowed us to test this approach.
To determine how well SuperBiHelix can recognize active and
inactive forms of the same receptor, we looked at the mutant
of the cannabinoid receptor CB1 that is constitutively active.
Kendall and coworkers identified a single-point mutant T3.46A
that was completely inactive and one (T3.46I) that was more
active than the WT receptor based on ligand-binding profiles (6)
and recently confirmed by the GTPγS assays (7). To determine
the origin of these major changes in activity, the SuperBiHelix/
SuperCombiHelix methods were applied to the three receptor
forms (WT and two single-point mutants T3.46A and T3.46I) to
predict the ensemble of low-energy seven-helix bundle con-
formations. We found substantially different TM helix packings
among the WT and mutant receptors that lead to markedly
different coupling of the charged residues near each receptor’s
cytoplasmic region (Fig. 7 A–C). Both WT and T3.46A exhibited
TM3+TM6 coupling, known to be critical to keep GPCRs in-
active. The fully inactive T3.46A mutant constrained TM6 fur-
ther through a TM2+TM6 coupling (R2.37+D6.30) explaining
its full inactivity. In contrast, the highly constitutively active
T3.46I mutant showed no coupling of TM6 to TM2 or TM3, but
rather had a TM5+TM6 coupling, similar to that observed in
active GPCR crystal structures. This shows that SuperBiHelix is
able to sample and capture conformations with structural dif-
ferences that explain the binding and activation assays leading to
concepts consistent with those extracted from GPCR crystal
structures as well.
To further validate these findings, we designed double
mutants to reverse the activity of the single mutants. Thus, we
Fig. 6. (A) The ZM241385-bound A2A adenosine crystal structure. (B)
ZM241385 docked into the A2A adenosine helices in the β2-adrenergic tem-
plate before SuperBiHelix. (C) ZM241385 docked into the A2A adenosine
helices in the β2-adrenergic template after SuperBiHelix.
Fig. 7. (A–C) Predicted structures of the T3.46A,
WT, and T3.46I CB1 GPCRs, showing the salt bridges
and hydrogen bonds formed on the cytoplasmic
side. (D) Comparison of basal GTPγS binding to
HEK293 cell membranes expressing the CB1 recep-
tors including the double mutants (8).
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predicted that the two double mutants (T3.46A/R2.37A and
T3.46A/R2.37Q) would regain WT constitutive activity. This
prediction was subsequently confirmed experimentally (see SI
Text for details) by the GTPγS assays (Fig. 7D), validating the
structures predicted with the SuperBiHelix methodology (7).
The structures lead to an activation mechanism for CB1 that
explains all experiments and that may play a role in other
GPCRs. Additional mutants have also been designed and then
tested in GTPγS assays (8), lending strong support to this ac-
tivation mechanism.
The CB1 example shows that the SuperBiHelix methodology
can be used to predict and design (based on testable hypothesis)
active conformations. SuperBiHelix was able to guide experi-
ments by predicting gain of function experiments (like making
the inactive T3.46A mutant constitutively active by adding a well-
chosen mutation). Thus, coupled to experiments to provide
functional validations, SuperBiHelix methodology can be used to
provide very specific tests of specific hypotheses probing the
structural basis of GPCR activation.
Discussion
In addition to CB1 (7, 8), SuperBiHelix has been applied suc-
cessfully to the adenosine A3 receptor (16) and other adeno-
sine receptors (22), serotonin 5-HT2B and 5-HT2C receptor
(25), the histamine H3 receptor (26), the CCR5 receptor (27,
28), TAS2R38 bitter taste receptor (29), and the V2 vasopressin
receptor (30). The predicted GPCR structures in these studies
were validated by predicting the binding sites and energies for
known series of ligands and comparing with experimental mu-
tagenesis, binding, and/or functional data. These predicted li-
gand–protein structures provided molecular-level interpretations
for structural or functional observations in the CCR5 and V2
receptors. Indeed, for A3 adenosine receptor (16), it was found
that all four selective agonists preferred the 15th WT confor-
mation, whereas the four selective antagonists all preferred the
second or the third conformations. Moreover, all of the agonists
caused the “trigger” Trp in TM6 (6.48) to switch from vertical
before binding to horizontal after binding.
We showed in Validation that SuperBiHelix does better than
homology modeling. β2-Adrenergic crystal helices in the A2A
adenosine template have a 2.0-Å homology model rmsd, which
SuperBiHelix improves to 1.6-Å rmsd. Similarly, A2A adenosine
crystal helices in the β2-adrenergic template have a 2.1-Å ho-
mology model rmsd, which SuperBiHelix improves to 1.4 Å. In
community-wide assessments of structure prediction methods
(31, 32) aimed at GPCRs, the SuperBiHelix method has per-
formed well at predicting the receptor structures. Prediction of
ligand binding sites (without using prior mutagenesis data on the
ligand or similar ligands) has not performed as well because
docking of ligands to predicted protein structures depends highly
on the accuracy of the protein structure. Homology-based meth-
ods have not led to the prediction of multiple receptor con-
formations like that possible with the SuperBiHelix method. Only
a handful of methods (18, 32) have been able to predict multi-
ple conformations based on some level of rigorous conforma-
tional sampling.
SuperBiHelix and SuperComBiHelix allow for the efficient
sampling of GPCR conformational space. This makes it possible
to predict structures of receptors that are dissimilar to any ex-
perimental crystal structure. It also predicts an ensemble of low-
lying structures, mirroring the flexibility of GPCR structures.
When helices from one crystal structure are placed into the tem-
plate of another structure, SuperBiHelix and SuperComBiHelix
successfully move the experimental helices closer to their origi-
nal template. The procedure also improves binding-site predic-
tions and makes ligand-binding calculations more accurate. The
success of SuperBiHelix and SuperComBiHelix on experimental
crystal structures can now lead to better predictions of GPCR
structures and binding sites, and therefore more successful ra-
tional drug design. The computational methodology can also be
used to probe GPCR activation as was highlighted by designing
a constitutively active mutant based on an inactive CB1 receptor
mutant. It shows the strength of the methodology to complement
and guide experiments in exploring many structural hypotheses
of GPCR activation and function.
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